

Hyperliquid revenue jumps 21.7% to $190.9 million as Trump backs CFTC efforts to open the platform to US traders.
You can purchase shares of Hyperliquid Strategies (NASDAQ:PURR) through any online brokerage.
Other companies in Hyperliquid Strategies’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Hyperliquid Strategies has a consensus price target of $17.20.
The stock price for Hyperliquid Strategies (NASDAQ: PURR) is $8.67 last updated November 13, 2026 at 1:14 PM EST.
There are no upcoming dividends for Hyperliquid Strategies.
Hyperliquid Strategies does not have any upcoming earnings scheduled.
There is no upcoming split for Hyperliquid Strategies.
Hyperliquid Strategies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. HSI...